Skip to Content

'
Nizar M. Tannir, MD, FACP

Present Title & Affiliation

Primary Appointment

Professor, Department of Genitourinary Medical Oncology, Division of Cancer Medicine, The University of Texas MD Anderson Cancer Center, Houston
Deputy Department Chair, Department of Genitourinary Medical Oncology, Division of Cancer Medicine, The University of Texas MD Anderson Cancer Center, Houston, TX

Research Interests

There has been significant progress made in the treatment of clear-cell renal cell carcinoma (RCC), with several targeted agents now approved.  However, the vast majority of patients develop progressive disease within a year. Despite the clinical efficacy of targeted agents, significant toxicity hampers patient benefit, and <30% of patients with metastatic RCC survive >five years. Furthermore, insight into the biology of non-clear cell RCC subtypes has lagged behind clear-cell RCC, with few relevant targets identified. Currently, there is no established effective therapy for this diverse group of non-clear cell RCC subtypes. Therapeutic strategies using immune checkpoint antibodies are revolutionizing the treatment of many cancers including RCC, but at best 50% of patients with metastatic RCC respond to the combination of anti-PD-1 and anti-CTLA-4 antibodies. The long-term follow-up of patients with metastatic RCC treated with these novel immune approaches will be awaited to assess their curative potential. 

My research focus in RCC is in the following areas:

  • Clinical and molecular characterization of non-clear cell RCC subtypes, particularly translocation RCC and renal medullary carcinoma
  • Design and conduct of informative, biology-driven clinical trials for clear-cell and non-clear cell RCC
  • Identification of circulating and tissue-based biomarkers of response to targeted agents and immune checkpoint antibodies in patients with clear-cell and non-clear cell RCC

The projects outlined above are currently being carried out in the context of several investigator-initiated, approved, and funded clinical and laboratory trials in metastatic clear-cell and non-clear cell RCC, on which I serve as principal investigator.

Office Address

The University of Texas MD Anderson Cancer Center
1155 Pressler Street
Unit Number: 1374
Houston, TX 77030
Room Number: CPB7.3470
Fax: 713-745-0422

Education & Training

Degree-Granting Education

1979 American University of Beirut, Beirut, Lebanon, MD, Medicine
1975 American University of Beirut, Beirut, Lebanon, BS, Biology/Chemistry

Postgraduate Training

8/2000-11/2000 Clinical Fellowship, Leukemia, The University of Texas MD Anderson Cancer Center, Houston, TX
7/1985-6/1986 Clinical Fellowship, Hematology, University of Medicine and Dentistry of New Jersey, Newark, NJ
7/1981-6/1984 Clinical Fellowship, Medical Oncology, The University of Texas MD Anderson Hospital and Tumor Institute, Houston, TX

Board Certifications

11/2000 American Board of Internal Medicine/Hematology
11/2000 American Board Internal Medicine/Medical Oncology
1/1987 American Board Internal Medicine/Medical Oncology
1/1986 American Board of Internal Medicine/Hematology
1/1985 American Board of Internal Medicine

Experience/Service

Academic Appointments

Associate Professor, Department of Genitourinary Medical Oncology, Division of Cancer Medicine, The University of Texas MD Anderson Cancer Center, Houston, TX, 9/2007-8/2014
Assistant Professor, Department of Genitourinary Medical Oncology, Division of Cancer Medicine, The University of Texas M.D. Anderson Cancer Center, Houston, TX, 3/2001-8/2007
Visiting Scientist, Department of Leukemia, Division of Cancer Medicine, The University of Texas M. D. Anderson Cancer Center, Houston, TX, 5/2000-7/2000

Administrative Appointments/Responsibilities

Director, Genitourinary Medical Oncology Clinic, Department of Genitourinary Medical Oncology, Division of Cancer Medicine, The University of Texas MD Anderson Cancer Center, Houston, TX, 2008-present
Director, Kentucky Cancer Clinic, Hazard, KY, 11/1997-12/1999
Voluntary Faculty, University of Kentucky, Lexington, KY, 11/1986-12/1999

Other Appointments/Responsibilities

Private Practice; Hematology Oncology, Appalachian Regional Medical Center, Hazard, KY, 11/1986-12/1999

Institutional Committee Activities

Chair, Division of Cancer Medicine Clinical Competency Committee, 1/2014-present
Member, Division of Cancer Medicine Clinical Competency Committee, 1/2013-12/2013
Member, Clinical Research and Patient Care Committee, 9/2011-present
Member, Division of Cancer Medicine Hematology/Oncology Fellowship Program Steering Committee, 9/2009-present

Honors and Awards

2014 Melvin L. Samuels Award for Excellence in Patient Care, The University of Texas MD Anderson Cancer Center, Division of Cancer Medicine Faculty Recognition and Awards
2014 Waun Ki Hong Leadership in Education, The University of Texas MD Anderson Cancer Center, Division of Cancer Medicine
2013 Division of Cancer Medicine Hematology/Oncology Fellowship Program 2013 "Teacher of the Year", The University of Texas MD Anderson Cancer Center
2013 Gerald P. Bodey Award for Excellence in Education, The University of Texas MD Anderson Cancer Center, Division of Cancer Medicine Faculty Recognition and Awards
2012 Division of Cancer Medicine Hematology/Oncology Fellowship Program 2012 "Teacher of the Year", The University of Texas MD Anderson Cancer Center
2012 Top Doctor 2012, US News and World Report
2011 Top Doctor 2011, US News and World Report
2010 Division of Cancer Medicine Hematology/Oncology Fellowship Program 2010 "Teacher of the Year", The University of Texas MD Anderson Cancer Center
2008 America's Top Oncologist, Guide to America's Top Oncologists
2008 Division of Cancer Medicine Hematology/Oncology Fellowship Program 2008 "Teacher of the Year", The University of Texas MD Anderson Cancer Center
2008 Vicente Valero LBJ Clinician-Educator of the Year, LBJ Hospital / The University of Texas MD Anderson Cancer Center
2001 Benefactors Award, Governor of Kentucky

Selected Publications

Peer-Reviewed Original Research Articles

1. Jonasch E, Liu X-D, Yao J, Tripathi D, Ding Z, Xu Y, Sun M, Zhang J, Bai S, German P, Hoang A, Zhou L, Jonasch D, Zhang X, Conti C, Efstathiou E, Tannir N, Eissa NT, Mills G, Walker C. Autophagy mediates HIF2α degradation and suppresses renal tumorigenesis. Oncogene. In Press.
2. Campbell MT, Millikan RE, Altinmakas E, Xiao L, Wen S, Siefker-Radtke AO, Aparicio A, Corn PG, Tannir NM. Phase I trial of sunitinib and temsirolimus in metastatic renal cell carcinoma. Clin Genitour Cancer. In Press.
3. Tu SM, Bilen M, Tannir NM. The scientific method: pillar and pitfall of cancer research. Can Med. In Press.
4. Thomas AZ, Adibi M, Borregales LD, Hoang LN, Tamboli P, Jonasch E, Tannir NM, Matin SF, Wood CG, Karam JA. Surgical Management for Local Retroperitoneal Recurrence Of Renal Cell Carcinoma After Radical Nephrectomy. J Urol. e-Pub 3/7/2015. PMID: 25758610.
5. Merrill MM, Wood CG, Tannir NM, Slack RS, Babaian KN, Jonasch E, Pagliaro LC, Compton Z, Tamboli P, Sircar K, Pisters LL, Matin SF, Karam JA. Clinically nonmetastatic renal cell carcinoma with sarcomatoid dedifferentiation: Natural history and outcomes after surgical resection with curative intent. Urol Oncol. e-Pub 2/17/2015. PMID: 25700975.
6. Thekdi SM, Milbury K, Spelman A, Wei Q, Wood C, Matin SF, Tannir N, Jonasch E, Pisters L, Cohen L. Posttraumatic stress and depressive symptoms in renal cell carcinoma: association with quality of life and utility of single-item distress screening. Psychooncology. e-Pub 2/17/2015. PMID: 25690556.
7. Karam JA, Babaian KN, Tannir NM, Matin SF, Wood CG. Role of partial nephrectomy as cytoreduction in the management of metastatic renal cell carcinoma. Minerva Urol Nefrol. e-Pub 2/3/2015. PMID: 25645343.
8. Melkonian SC, Wang X, Gu J, Matin SF, Tannir NM, Wood CG, Wu X. Mitochondrial DNA Copy Number in Peripheral Blood Leukocytes and the Risk of Clear Cell Renal Cell Carcinoma. Carcinogenesis. e-Pub 12/18/2014. PMID: 25524925.
9. Land JD, Chen AH, Atkinson BJ, Cauley DH, Tannir NM. Proteinuria with first-line therapy of metastatic renal cell cancer. J Oncol Pharm Pract. e-Pub 12/9/2014. PMID: 25505255.
10. Teegavarapu PS, Rao P, Matrana MR, Cauley DH, Wood CG, Tannir NM. Neuroendocrine Tumors of the Kidney: A Single Institution Experience. Clin Genitour Cancer 12(6):422-27, 12/2014. NIHMSID: NIHMSNIHMS618553.
11. Shetty AV, Matrana MR, Atkinson BJ, Flaherty AL, Jonasch E, Tannir NM. Outcomes of patients with metastatic renal cell carcinoma and end-stage renal disease receiving dialysis and targeted therapies: A single institution experience. Clin Genitourin Cancer 12(5):348-53, 10/2014. e-Pub 1/18/2014. PMCID: PMC4160412.
12. Melkonian SC, Daniel CR, Hildebrandt MA, Tannir NM, Ye Y, Chow WH, Wood CG, Wu X. Joint Association of Genome-Wide Association Study-Identified Susceptibility Loci and Dietary Patterns in Risk of Renal Cell Carcinoma Among Non-Hispanic Whites. Am J Epidemiol 180(5):499-507, 9/1/2014. e-Pub 7/22/2014. PMCID: PMC4143080.
13. Teegavarapu PS, Rao P, Matrana MR, Cauley DH, Wood CG, Patel S, Tannir NM. Outcomes of Adults With Ewing Sarcoma Family of Tumors (ESFT) of the Kidney: A Single-Institution Experience. Am J Clin Oncol. e-Pub 9/12/2014. PMID: 25222071.
14. Tannir NM, Forero-Torres A, Ramchandren R, Pal SK, Ansell SM, Infante JR, de Vos S, Hamlin PA, Kim SK, Whiting NC, Gartner EM, Zhao B, Thompson JA. Phase I dose-escalation study of SGN-75 in patients with CD70-positive relapsed/refractory non-Hodgkin lymphoma or metastatic renal cell carcinoma. Invest New Drugs. e-Pub 8/22/2014. PMID: 25142258.
15. Malouf GG, Zhang J, Yuan Y, Compérat E, Rouprêt M, Cussenot O, Chen Y, Thompson EJ, Tannir NM, Weinstein JN, Valero V, Khayat D, Spano JP, Su X. Characterization of long non-coding RNA transcriptome in clear-cell renal cell carcinoma by next-generation deep sequencing. Mol Oncol. e-Pub 7/25/2014. PMID: 25126716.
16. Jardim DL, de Melo Gagliato D, Falchook G, Zinner R, Wheler JJ, Janku F, Subbiah V, Piha-Paul SA, Fu S, Tannir N, Corn P, Tang C, Hess K, Roy-Chowdhuri S, Kurzrock R, Meric-Bernstam F, Hong DS. MET Abnormalities in Patients With Genitourinary Malignancies and Outcomes With c-MET Inhibitors. Clin Genitourin Cancer. e-Pub 7/3/2014. PMID: 25087088.
17. Prinsloo S, Wei Q, Scott SM, Tannir N, Jonasch E, Pisters L, Cohen L. Psychological states, serum markers and survival: associations and predictors of survival in patients with renal cell carcinoma. J Behav Med. e-Pub 6/17/2014. PMID: 24935017.
18. Hong DS, Gordon MS, Samlowski WE, Kurzrock R, Tannir N, Friedland D, Mendelsohn DS, Vogelzang NJ, Rasmussen E, Wu BM, Bass MB, Zhong ZD, Friberg G, Appleman LJ. A phase I, open-label study of trebananib combined with sorafenib or sunitinib in patients with advanced renal cell carcinoma. Clin Genitourin Cancer 12(3):167-177.e2, 6/2014. e-Pub 11/2013. PMID: 24365125.
19. Malouf GG, Su X, Yao H, Gao J, Xiong L, He Q, Compérat E, Couturier J, Molinie V, Escudier B, Camparo P, Doss DJ, Thompson EJ, Khayat D, Wood CG, Yu W, Teh BT, Weinstein JN, Tannir NM. Next generation sequencing of translocation renal cell carcinomas reveals novel RNA splicing partners and frequent mutations of chromatin remodeling genes. Clin Cancer Res. e-Pub 6/2014. PMID: 24899691.
20. Burch-Smith R, Tannir NM, Resetkova E, Tamboli P, Rao P. Collision tumor of the kidney composed of clear cell carcinoma and collecting duct carcinoma: report of a case with unusual morphology and clinical follow up. Chin J Cancer. e-Pub 3/4/2014. PMID: 24589208.
21. Milbury K, Spelman A, Wood C, Matin SF, Tannir N, Jonasch E, Pisters L, Wei Q, Cohen L. Randomized controlled trial of expressive writing for patients with renal cell carcinoma. J Clin Oncol 32(7):663-70, 3/1/2014. e-Pub 1/27/2014. PMCID: PMC3927735.
22. Atkinson BJ, Kalra S, Wang X, Bathala T, Corn P, Tannir NM, Jonasch E. Clinical outcomes in metastatic renal cell carcinoma patients treated with alternative sunitinib schedules. J Urol 191(3):611-8, 3/2014. e-Pub 9/7/2013. PMID: 24018239.
23. Atkinson BJ, Cauley DH, Ng C, Millikan RE, Xiao L, Corn P, Jonasch E, Tannir NM. Mammalian target of rapamycin (mTOR) inhibitor-associated non-infectious pneumonitis in patients with renal cell cancer: predictors, management, and outcomes. BJU Int 113(3):376-82, 3/2014. e-Pub 12/2/2013. PMCID: PMC3944913.
24. Babaian KN, Merrill MM, Matin S, Tamboli P, Tannir NM, Jonasch E, Wood CG, Karam JA. Partial nephrectomy in the setting of metastatic renal cell carcinoma. J Urol. e-Pub 2/8/2014. PMID: 24518767.
25. Karam JA, Devine CE, Urbauer DL, Lozano M, Maity T, Ahrar K, Tamboli P, Tannir NM, Wood CG. Phase 2 trial of neoadjuvant axitinib in patients with locally advanced nonmetastatic clear cell renal cell carcinoma. Eur Urol. e-Pub 2/2014. PMID: 24560330.
26. Verma J, Jonasch E, Allen PK, Weinberg JS, Tannir N, Chang EL, Mahajan A. The impact of tyrosine kinase inhibitors on the multimodality treatment of brain metastases from renal cell carcinoma. Am J Clin Oncol 36(6):620-4, 12/2013. e-Pub 8/2012. PMID: 22892430.
27. Matrana MR, Duran C, Shetty A, Xiao L, Atkinson BJ, Corn P, Pagliaro LC, Millikan RE, Charnsangave C, Jonasch E, Tannir NM. Outcomes of patients with metastatic clear-cell renal cell carcinoma treated with pazopanib after disease progression with other targeted therapies. Eur J Cancer 49(15):3169-75, 10/2013. e-Pub 6/2013. PMCID: PMC3882156.
28. Richey SL, Tamboli P, Ng CS, Lin E, Lim ZD, Araujo JC, Jonasch E, Sharma P, Pagliaro LC, Tannir NM. Phase II trial of pemetrexed plus gemcitabine in patients with locally advanced and metastatic nonclear cell renal cell carcinoma. Am J Clin Oncol 36(5):450-4, 10/2013. e-Pub 6/2012. PMCID: PMC3882166.
29. Conter HJ, Lim ZD, Ng CS, Millikan RE, Tannir NM. Curability of poor-risk metastatic sarcomatoid renal cell carcinoma with the combination of gemcitabine, 5-fluorouracil, and interferon-alfa: A case report of a 55-year-old man with a 10-year complete remission. Clin Genitourin Cancer 11(3):370-3, 9/2013. e-Pub 5/2013. PMID: 23665133.
30. Malouf GG, Monzon FA, Couturier J, Molinié V, Escudier B, Camparo P, Su X, Yao H, Tamboli P, Lopez-Terrada D, Picken M, Garcia M, Multani AS, Pathak S, Wood CG, Tannir NM. Genomic heterogeneity of translocation renal cell carcinoma. Clin Cancer Res 19(17):4673-4684, 9/2013. e-Pub 7/2013. PMCID: PMC3882157.
31. Anzalone CL, Cohen PR, Migden MR, Tannir NM. Mohs surgery in metastatic cancer: renal cell carcinoma solitary cutaneous metastasis and visceral tumor metastases to skin treated with microscopically controlled surgical excision. Int J Dermatol 52(7):856-61, 7/2013. e-Pub 5/2013. PMID: 23675612.
32. Parker PA, Alba F, Fellman B, Urbauer DL, Li Y, Karam JA, Tannir N, Jonasch E, Wood CG, Matin SF. Illness uncertainty and quality of life of patients with small renal tumors undergoing watchful waiting: A 2-year prospective study. Eur Urol 63(6):1122-1127, 6/2013. e-Pub 2/9/2013. PMID: 23419322.
33. Lim ZD, Mahajan A, Weinberg J, Tannir NM. Outcome of patients with renal cell carcinoma metastatic to the brain treated with sunitinib without local therapy. Am J Clin Oncol 36(3):258-60, 6/2013. e-Pub 3/20/2012. PMID: 22441343.
34. Margulis V, Shariat SF, Rapoport Y, Rink M, Sjoberg DD, Tannir NM, Abel EJ, Culp SH, Tamboli P, Wood CG. Development of accurate models for individualized prediction of survival after cytoreductive nephrectomy for metastatic renal cell carcinoma. Eur Urol 63(5):947-52, 5/2013. e-Pub 11/23/2012. PMID: 23273681.
35. Karam JA, Ahrar K, Vikram R, Romero CA, Jonasch E, Tannir NM, Rao P, Wood CG, Matin SF. Radiofrequency ablation of renal tumours with clinical, radiographical and pathological results. BJU Int 111(6):997-1005, 5/2013. e-Pub 3/2013. PMCID: PMC3637414.
36. Shu X, Lin J, Wood CG, Tannir NM, Wu X. Energy balance, polymorphisms in the mTOR pathway, and renal cell carcinoma risk. J Natl Cancer Inst 105(6):424-32, 3/20/2013. e-Pub 2/2/2013. PMCID: PMC3601952.
37. Rini B, Szczylik C, Tannir NM, Koralewski P, Tomczak P, Deptala A, Dirix LY, Fishman M, Ramlau R, Ravaud A, Rogowski W, Kracht K, Sun YN, Bass MB, Puhlmann M, Escudier B. AMG 386 in combination with sorafenib in patients with metastatic clear cell carcinoma of the kidney: a randomized, double-blind, placebo-controlled, phase 2 study. Cancer 118(24):6152-61, 12/15/2012. e-Pub 6/12/2012. PMID: 22692704.
38. Tannir NM, Plimack E, Ng C, Tamboli P, Bekele NB, Xiao L, Smith L, Lim Z, Pagliaro L, Araujo J, Aparicio A, Matin S, Wood CG, Jonasch E. A phase 2 trial of sunitinib in patients with advanced non-clear cell renal cell carcinoma. Eur Urol 62(6):1013-9, 12/2012. e-Pub 6/2012. PMCID: PMC3882163.
39. Abel EJ, Carrasco A, Culp SH, Matin SF, Tamboli P, Tannir NM, Wood CG. Limitations of preoperative biopsy in patients with metastatic renal cell carcinoma: comparison to surgical pathology in 405 cases. BJU Int 110(11):1742-6, 12/2012. e-Pub 4/13/2012. PMID: 22503066.
40. Richey SL, Rao P, Wood CG, Patel S, Tannir NM. Metastatic extraosseous Ewing's sarcoma (EES)/Primitive Neuroectodermal Tumor (PNET) of the kidney: 8-year durable response after induction and maintenance chemotherapy. Clin Genitourin Cancer 10(3):210-2, 9/2012. e-Pub 4/2012. NIHMSID: NIHMSNIHMS611584.
41. Rao P, Tannir NM, Tamboli P. Expression of OCT3/4 in renal medullary carcinoma represents a potential diagnostic pitfall. Am J Surg Pathol 36(4):583-8, 4/2012. e-Pub 2012. PMID: 22301499.
42. Zurita AJ, Jonasch E, Wang X, Khajavi M, Yan S, Du DZ, Xu L, Herynk MH, McKee KS, Tran HT, Logothetis CJ, Tannir NM, Heymach JV. A cytokine and angiogenic factor (CAF) analysis in plasma for selection of sorafenib therapy in patients with metastatic renal cell carcinoma. Ann Oncol 23(1):46-52, 1/2012. e-Pub 4/2011. PMCID: PMC3276320.
43. Cohen L, Cole SW, Sood AK, Prinsloo S, Kirschbaum C, Arevalo JM, Jennings NB, Scott S, Vence L, Wei Q, Kentor D, Radvanyi L, Tannir N, Jonasch E, Tamboli P, Pisters L. Depressive symptoms and cortisol rhythmicity predict survival in patients with renal cell carcinoma: role of inflammatory signaling. PLoS One 7(8):e42324, 2012. e-Pub 8/2012. PMCID: PMC3409855.
44. Matrana MR, Ng C, Rao P, Lim ZD, Tannir NM. Chromophobe renal cell carcinoma with sarcomatoid dedifferentiation treated with pazopanib: a case report. Clin Genitourin Cancer 9(2):137-9, 12/2011. e-Pub 8/10/2011. PMID: 21831725.
45. Abel EJ, Culp SH, Tannir NM, Tamboli P, Matin SF, Wood CG. Early primary tumor size reduction Is an independent predictor of improved overall survival in metastatic renal cell carcinoma patients treated with sunitinib. Eur Urol 60(6):1273-9, 12/2011. e-Pub 7/2011. PMID: 21784574.
46. Tannir NM, Wong YN, Kollmannsberger CK, Ernstoff MS, Perry DJ, Appleman LJ, Posadas EM, Cho D, Choueiri TK, Coates A, Gupta N, Pradhan R, Qian J, Chen J, Scappaticci FA, Ricker JL, Carlson DM, Michaelson MD. Phase 2 trial of linifanib (ABT-869) in patients with advanced renal cell cancer after sunitinib failure. Eur J Cancer 47(18):2706-14, 12/2011. e-Pub 11/2011. PMID: 22078932.
47. Manoukian GE, Tannir NM, Jonasch E, Qiao W, Haygood TM, Tu SM. Pilot trial of bone-targeted therapy combining zoledronate with fluvastatin or atorvastatin for patients with metastatic renal cell carcinoma. Clin Genitourin Cancer 9(2):81-8, 12/2011. e-Pub 10/2011. PMID: 21958521.
48. Milbury K, Tannir NM, Cohen L. Treatment-related optimism protects quality of life in a phase II clinical trial for metastatic renal cell carcinoma. Ann Behav Med 42(3):313-20, 12/2011. e-Pub 2011. PMID: 21822749.
49. Verma J, Jonasch E, Allen P, Tannir N, Mahajan A. Impact of tyrosine kinase inhibitors on the incidence of brain metastasis in metastatic renal cell carcinoma. Cancer 117(21):4958-65, 11/1/2011. e-Pub 4/11/2011. PMID: 21484781.
50. Monzon FA, Alvarez K, Peterson L, Truong L, Amato RJ, Hernandez-McClain J, Tannir N, Parwani AV, Jonasch E. Chromosome 14q loss defines a molecular subtype of clear cell renal cell carcinoma associated with poor prognosis. Mod Pathol 24(11):1470-9, 11/2011. e-Pub 7/1/2011. PMID: 21725288.
51. Chapin BF, Delacroix SE, Culp SH, Nogueras Gonzalez GM, Tannir NM, Jonasch E, Tamboli P, Wood CG. Safety of presurgical targeted therapy in the setting of metastatic renal cell carcinoma. Eur Urol 60(5):964-71, 11/2011. e-Pub 5/25/2011. PMID: 21621907.
52. Choueiri M, Tannir N, Jonasch E. Adjuvant and neoadjuvant therapy in renal cell carcinoma. Curr Clin Pharmacol 6(3):144-50, 8/2011. PMID: 21827393.
53. Matrana MR, Atkinson B, Jonasch E, Tannir NM. Emerging targeted therapies in metastatic renal cell carcinoma. Curr Clin Pharmacol 6(3):189-98, 8/2011. PMID: 21827388.
54. Chowdhury S, Matrana MR, Tsang C, Atkinson B, Choueiri TK, Tannir NM. Systemic therapy for metastatic non-clear-cell renal cell carcinoma: Recent progress and future directions. Hematol Oncol Clin North Am 25(4):853-869, 8/2011. PMID: 21763971.
55. Pagliaro LC, Tannir N, Sircar K, Jonasch E. Systemic therapy for sarcomatoid renal cell carcinoma. Expert Rev Anticancer Ther 11(6):913-20, 6/2011. PMID: 21707288.
56. Richey SL, Culp SH, Jonasch E, Corn PG, Pagliaro LC, Tamboli P, Patel KK, Matin SF, Wood CG, Tannir NM. Outcome of patients with metastatic renal cell carcinoma treated with targeted therapy without cytoreductive nephrectomy. Ann Oncol 22(5):1048-53, 5/2011. e-Pub 11/29/2010. PMID: 21115604.
57. Richey SL, Ng C, Lim ZD, Jonasch E, Tannir NM. Durable remission of metastatic renal cell carcinoma with gemcitabine and capecitabine after failure of targeted therapy. J Clin Oncol 29(8):e203-5, 3/10/2011. e-Pub 12/20/2010. PMID: 21172884.
58. Jonasch E, Lal LS, Atkinson BJ, Byfield SD, Miller LA, Pagliaro LC, Feng C, Tannir NM. Treatment of metastatic renal carcinoma patients with the combination of gemcitabine, capecitabine, and bevacizumab at a tertiary cancer center. BJU Int 107(5):741-7, 3/2011. e-Pub 9/2010. PMID: 21355978.
59. Karam JA, Rini BI, Varella L, Garcia JA, Dreicer R, Choueiri TK, Jonasch E, Matin SF, Campbell SC, Wood CG, Tannir NM. Metastasectomy after targeted therapy in patients with advanced renal cell carcinoma. J Urol 185(2):439-44, 2/2011. e-Pub 12/17/2010. PMID: 21167518.
60. Abel EJ, Culp SH, Tannir NM, Matin SF, Tamboli P, Jonasch E, Wood CG. Primary tumor response to targeted agents in patients with metastatic renal cell carcinoma. Eur Urol 59(1):10-5, 1/2011. e-Pub 10/16/2010. PMID: 20952123.
61. Dhillon J, Tannir NM, Matin SF, Tamboli P, Czerniak BA, Guo CC. Thyroid-like follicular carcinoma of the kidney with metastases to the lungs and retroperitoneal lymph nodes. Hum Pathol 42(1):146-50, 1/2011. e-Pub 10/2010. PMID: 20971497.
62. Jonasch E, Pagliaro LC, Tannir NM. Long-term management of patients with metastatic renal cell carcinoma on targeted agents. Expert Rev Anticancer Ther 10(12):1883-9, 12/2010. PMID: 21110755.
63. Choueiri TK, Lim ZD, Hirsch MS, Tamboli P, Jonasch E, McDermott DF, Dal Cin P, Corn P, Vaishampayan U, Heng DY, Tannir NM. Vascular endothelial growth factor (VEGF)-targeted therapy for the treatment of adult metastatic Xp11.2 translocation renal cell carcinoma. Cancer 116(22):5219-25, 11/15/2010. e-Pub 2010. PMID: 20665500.
64. Abel EJ, Culp SH, Matin SF, Tamboli P, Wallace MJ, Jonasch E, Tannir NM, Wood CG. Percutaneous biopsy of primary tumor in metastatic renal cell carcinoma to predict high risk pathological features: comparison with nephrectomy assessment. J Urol 184(5):1877-81, 11/2010. e-Pub 9/17/2010. PMID: 20850148.
65. Karam JA, Ahrar K, Wood CG, Jonasch E, Vikram R, Romero C, Tannir N, Matin SF. Radiofrequency ablation of renal tumors in patients with metastatic renal cell carcinoma. J Urol 184(5):1882-7, 11/2010. e-Pub 9/17/2010. PMID: 20846689.
66. Tsavachidou-Fenner D, Tannir N, Tamboli P, Liu W, Petillo D, Teh B, Mills GB, Jonasch E. Gene and protein expression markers of response to combined antiangiogenic and epidermal growth factor targeted therapy in renal cell carcinoma. Ann Oncol 21(8):1599-606, 8/2010. e-Pub 1/2010. PMID: 20089566.
67. Culp SH, Tannir NM, Abel EJ, Margulis V, Tamboli P, Matin SF, Wood CG. Can we better select patients with metastatic renal cell carcinoma for cytoreductive nephrectomy? Cancer 116(14):3378-88, 7/15/2010. PMID: 20564061.
68. Jonasch E, Tannir NM. Targeted therapy for locally advanced renal cell carcinoma. Target Oncol 5(2):113-8, 6/2010. e-Pub 7/14/2010. PMID: 20625844.
69. Ng CS, Wang X, Faria SC, Lin E, Charnsangavej C, Tannir NM. Perfusion CT in patients with metastatic renal cell carcinoma treated with interferon. Am J Roentgenol 194(1):166-71, 1/2010. PMID: 20028919.
70. Jonasch E, Corn P, Pagliaro LC, Warneke CL, Johnson MM, Tamboli P, Ng C, Aparicio A, Ashe RG, Wright JJ, Tannir NM. Upfront, randomized, phase 2 trial of sorafenib versus sorafenib and low-dose interferon alfa in patients with advanced renal cell carcinoma: clinical and biomarker analysis. Cancer 116(1):57-65, 1/2010. e-Pub 10/2009. PMID: 19862815.
71. Chen M, Ye Y, Yang H, Tamboli P, Matin S, Tannir NM, Wood CG, Gu J, Wu X. Genome-wide profiling of chromosomal alterations in renal cell carcinoma using high-density single nucleotide polymorphism arrays. Int J Cancer 125(10):2342-8, 11/2009. e-Pub 6/2009. PMCID: PMC2768265.
72. Montero A, Diaz-Montero C, Millikan R, Liu J, Do, D-A, Hodges S, Jonasch E, McIntyre B, Hwu P, Tannir N. Cytokines and angiogenic factors in metastatic renal cell cancer: association of pretreatment serum levels with survival. Ann Oncol 20(10):1682-7, 10/2009. PMID: 19541791.
73. Jonasch E, Wood CG, Matin SF, Tu S-M, Pagliaro LC, Corn PG, Aparicio A, Tamboli P, Millikan RE, Wang X, Araujo JC Arap W, Tannir N. Phase II presurgical feasibility study of bevacizumab in untreated patients with metastatic renal cell carcinoma. J Clin Oncol 27(25):4076-81, 9/2009. PMID: 19636008.
74. Rodney A, Gombos D, Fuller G, Pagliaro LC, Tannir N. Choroidal and conjunctival metastases from renal cell carcinoma. Am J Clin Oncol 32(4):448-9, 8/2009. PMID: 19657240.
75. Daliani DD, Tannir NM, Papandreou CN, Wang X, Swisher S, Wood CG, Swanson DA, Logothetis CJ, Jonasch E. Prospective assessment of systemic therapy followed by surgical removal of metastases in selected patients with renal cell carcinoma. BJU Int 104(4):456-60, 8/2009. PMID: 19338544.
76. Vikram R, Ng CS, Tamboli P, Tannir NM, Jonasch E, Matin SF, Wood C, Sandler CM. Papillary renal cell carcinoma: Radiologic-pathologic correlation and spectrum of disease. Radiographics 29(3):741-54; discussion 755-7, May-Jun, 5/2009. PMID: 19448113.
77. Plimack ER, Tannir N, Lin E, Bekele BN, Jonasch E. Patterns of disease progression in metastatic renal cell carcinoma patients treated with antivascular agents and interferon: impact of therapy on recurrence patterns and outcome measures. Cancer 115(9):1859-66, 5/2009. PMID: 19241453.
78. Clague J, Lin J, Cassidy A, Matin S, Tannir NM, Tamboli P, Wood CG, Wu X. Family history and risk of renal cell carcinoma: results from a case-control study and systematic meta-analysis. Cancer Epidemiol Biomarkers Prev 18(3):801-807, 2/2009. e-Pub 2/2009. PMID: 19240244.
79. Rodney A, Gombos D, Pagliaro LC, Tannir N. Ischemic optic neuropathy associated with low dose interferon alfa: Report of two cases. Am J Clin Oncol 32(1):86-87, 2/2009. NIHMSID: NIHMSNIHMS618553.
80. Dubauskas Z, Kunishige J, Prieto VG, Kantrow SM, Jonasch E, Hwy P, Tannir NM. Cutaneous squamous cell carcinoma and inflammation of actinic keratoses associated with sorafenib. Clin Genitourin Cancer 7(1):20-3, 1/2009. PMID: 19213663.
81. Margulis V, Matin SF, Tannir N, Tamboli P, Shen Y, Lozano M, Swanson DA, Jonasch E, Wood CG. A randomized trial of adjuvant thalidomide versus observation in patients with completely resected high risk renal cell carcinoma. Urology 73(2):337-41, 2009. e-Pub 10/31/2008. PMID: 18950837.
82. Lin J, Pu X, Wang W, Matin S, Tannir NM, Wood CG, Wu X. Case-control analysis of nucleotide excision repair pathway and the risk of renal cell carcinoma. Carcinogenesis 29(11):2112-2119, 11/2008. e-Pub 8/18/2008. PMID: 18711149.
83. Ng CS, Wood CG, Silverman PM, Tannir NM, Tamboli P, Sandler CM. Renal cell carcinoma: diagnosis, staging, and surveillance - Review. AJR Am J Roentgenol 191(4):1220-1230. Review, 10/2008. PMID: 18806169.
84. Tannir NM, Thall PF, Ng CS, Wang X, Wooten L, Siefker-Radtke A, Mathew P, Pagliaro, L, Wood C, Jonasch E. A phase II trial of gemcitabine plus capecitabine in metastatic renal cell cancer previously treated with immunotherapy and targeted agents. J Urol 180(3):867-72; discussion 872, 9/2008. NIHMSID: NIHMSNIHMS615126.
85. Bilen MA, Waguespack SG, Tannir NM, Pravinkumar SE, Tamboli P, Tu S-M. Multisystem crisis in a patient with presumptive renal cell carcinoma. Clin Genitourin Cancer 6(2):128-130, 9/2008. PMID: 18824438.
86. Jain R, Mathew P, Wood CG, Tannir NM. Sunitinib-induced acute hemolysis without hypertension: A case report. Clin Genitourin Cancer 6(2):122-123, 9/2008. PMID: 18824436.
87. Jonasch E, Wood C, Tamboli P. Pagliaro LC, Tu SM, Kim J, Sirvastava P, Perez C, Isakov L, Tannir N. Vaccination of metastatic renal cell carcinoma patients with autologous tumour-derived vitespen vaccine: clinical findings. Br J Cancer 98(8):1336-41, 4/2008. PMID: 18362942.
88. Jonasch E, Tannir NM. Adjuvant and neoadjuvant therapy in renal cell carcinoma. Cancer J 14(5):315-9, Sep-Oct, 2008. PMID: 18836336.
89. Margulis V, Matin SF, Tannir N, Tamboli P, Swanson DA, Jonasch E, Wood CG. Surgical morbidity associated with administration of targeted molecular therapies prior to cytoreductive nephrectomy or resection of locally recurrent renal cell carcinoma. J Urol 180(1):94-8, 2008. e-Pub 5/2008. PMID: 18485389.
90. Kassouf W, Sanchez-Ortiz R, Tamboli P, Tannir N, Jonasch E, Merchant MM, Matin SF, Swanson DA, Wood CG. Cytoreductive nephrectomy for metastatic renal cell carcinoma with non-clear histology. J Urol 178(5):1896-1900, 11/2007. e-Pub 9/2007. PMID: 17868729.
91. Shao L, Wood CG, Zhang D, Tannir NM, Matin S, Dinney CP, Wu X. Telomere dysfunction in peripheral lymphocytes as a potential predisposition factor for renal cancer. J Urol 178(4 Pt 1):1492-1496, 10/2007. e-Pub 8/2007. PMID: 17707063.
92. Lin PP, Mirza AN, Lewis VO, Cannon CP, Tu SM, Tannir NM, Yasko AW. Patient survival after surgery for osseous metastases from renal cell carcinoma. J Bone Joint Surg Am 89(8):1794-801, 8/2007. PMID: 17671020.
93. Thall PF, Wooten LH, Logothetis CJ, Millikan RE, Tannir NM. Bayesian and frequentist two-stage treatment strategies based on sequential failure times subject to interval censoring. Stat Med 26(26):4687-702, 4/2007. PMID: 17427204.
94. Nakayama K, Tannir NM, Liu P, Wathen JK, Cheng YC, Champlin RE, Ueno NT. Natural history of metastatic renal cell carcinoma in patients who underwent consultation for allogeneic hematopoietic stem cell transplantation. Biol Blood Marrow Transplant 13(8):975-985, 2007. PMID: 17640602.
95. Ebbinghaus S, Hussain M, Tannir N, Gordon M, Desai AA, Knight RA, Humerickhouse RA, Qian J, Gordon GB, Figlin R. Phase 2 study of ABT-510 in patients with previously untreated advanced renal cell carcinoma. Clin Cancer Res 13(22 Pt 1):6689-6695, 2007. PMID: 18006769.
96. Tannir NM, Cohen L, Wang X, Thall P, Mathew PF, Jonasch E, Siefker-Radtke A, Pagliaro LC, Ng CS, Logothetis C. Improved tolerability and quality of life with maintained efficacy using twice-daily low-dose interferon-alpha-2b: results of a randomized phase II trial of low-dose versus intermediate-dose interferon-alpha-2b in patients with metastatic renal cell carcinoma. Cancer 107(9):2254-61, 11/2006. PMID: 17029276.
97. Tannir N, Jonasch E, Pagliaro LC, Mathew P, Siefker-Radtke A, Rhines L, Lin P, Tibbs R, Do KA, Lin SH, Tu SM. Pilot trial of bone-targeted therapy with zoledronate, thalidomide, and interferon-gamma for metastatic renal cell carcinoma. Cancer 107(3):497-505, 2006. PMID: 16795067.
98. Ahrar K, Matin S, Wood CG, Wallace MJ, Gupta S, Madoff DC, Rao S, Tannir NM, Jonasch E, Pisters LL, Rozner MA, Kennamer DL, Hicks ME. Percutaneous radiofrequency ablation of renal tumors: technique, complications, and outcomes. J Vasc Interv Radiol 16(5):679-688, 5/2005. PMID: 15872323.
99. Sanchez-Ortiz RF, Tannir N, Ahrar K, Wood CG. Spontaneous regression of pulmonary metastases from renal cell carcinoma after radio frequency ablation of primary tumor: an in situ tumor vaccine? J Urol 170(1):178-179, 7/2003. PMID: 12796677.
Other Articles
1. Spiess PE, Tannir NM. Reply. Urol Oncol 27(2):218-9, Mar-Apr, 2009. PMID: 19285239.
2. Mehta KU, Gascon P, Tannir N, Lombardo J, Robboy SJ. Impaired bone marrow in AIDS. N J Med 86(8):623-627, 8/1989. PMID: 2685666.

Abstracts

1. Malouf G, Tannir NM. Long non-coding RNA subtype classification of clear-cell renal cell carcinoma. Proceedings Amer Assoc Can Res. In Press.
2. Malouf G, Zhang J, Tannir NM, Erika Thompson E, S J-P, Khayat D, Su X. Association of CpG island methylator phenotype with clear-cell renal cell carcinoma aggressiveness. J Clin Oncol 32(5s):suppl; abstr 4574, 2014.
3. Tannir NM, Jonasch E, Altinmakas Emre, Ng CS, Qiao W, Tamboli P, Rao P, McDermott DF, Wood CG, Choueiri T. Everolimus versus sunitinib prospective evaluation in metastatic non-clear cell renal cell carcinoma (The ESPN Trial): A multicenter randomized phase 2 trial. J Clin Oncol 32(5s):suppl; abstr 4505, 2014.
4. Gao J, Yao H, Su X, Rao P, Sharma P, Karam JA, Wood CG, Tannir NM. Molecular characterization of renal medullary carcinoma (RMC). J Clin Oncol 32(5s):suppl; abstr 4586, 2014.
5. Nieto Y, Tu S-M, Jones RB, Tannir NM, Bassett RL, Margolin DA, Holmberg L, Champlin RE, Pagliaro LC. Phase 2 trial of bevacizumab (BEV)/high-dose chemotherapy (HDC) with autologous stem-cell transplant (ASCT) for refractory germ-cell tumors (GCT). J Clin Oncol 32(5s):suppl; abstr 4517, 2014.
6. Matrana M, Shetty A, Teegavarapu P, Kalra S, Xiao L, Atkinson B, Corn P, Jonasch E, Tannir NM. Outcomes of unselected patients with metastatic renal cell carcinoma treated with front-line pazopanib therapy. Ann Oncol 24:2779, 10/2013.
7. Atkinson BJ, Kalra S, Wang X, Tannir NM, Jonasch E. A single-center retrospective review of outcomes associated with sunitinib alternative schedule compared to traditional schedule. J Clin Oncol 31(suppl 6):abstr 381, 2013.
8. Merrill MM, Wood CG, Tannir NM, Slack R, Babaian K, Jonasch E, Pagliaro LC, Compton Z, Tamboli P, Sircar K, Pisters LL, Matin SF, Karam JA. Characteristics and clinical outcomes of patients with renal cell carcinoma with sarcomatoid dedifferentiation (sRCC). J Clin Oncol 31(suppl 6):abstr 401, 2013.
9. Jonasch E, Thakur S, Sircar K, Tamboli P, Tannir NM, Monzon FA. Impact of chromosomal copy number variation on outcome in metastatic clear cell renal cell carcinoma patients treated with antiangiogenic agents. J Clin Oncol 31(suppl 6):abstr 393, 2013.
10. Matrana MR, Duran C, Shetty A, Xiao L, Atkinson BJ, Corn PG, Charnsangavej C, Jonasch E, Tannir NM. Outcomes of patients (pts) with metastatic renal cell carcinoma (mRCC) treated with pazopanib after progression on other targeted therapies (TT): Updates results. J Clin Oncol 31(suppl 6):abstr 367, 2013.
11. Babaian K, Matin SF, Tamboli P, Tannir NM, Jonasch E, Wood CG, Karam JA. Partial nephrectomy in the setting of metastatic renal cell carcinoma. J Clin Oncol 31(suppl 6):abstr 440, 2013.
12. Thompson JA, Forero A, Heath EI, Pal SK, Ansell SM, Infante JR, De Vos S, Hamlin PA, Whiting NC, Zhao B, Tannir NM. SGN-75 in the treatment of patients with CD70-positive malignancies including metastatic renal cell carcinoma. J Clin Oncol 31(suppl 6):abstr 368, 2013.
13. Conter HJ, Wood CG, Matin SF, Tamboli P, Millikan RE, Jonasch E, Tannir NM. Ten-year follow-up of patients (pts) with metastatic renal cell carcinoma (mRCC) treated with interferon alfa-2b (IFN) as first-line therapy: Results from a randomized trial. J Clin Oncol 31(suppl 6):abstr 365, 2013.
14. Jonasch E, Wood CG, Corn PG, Sharma P, Pagliaro LC, Aparicio A, Do K-A, Wang X, Marcott VD, Matin SF, Tannir NM. Using presurgical sunitinib to select patients with newly diagnosed metastatic clear cell renal cell carcinoma for cytoreductive nephrectomy: A phase II study. J Clin Oncol 31(suppl 6):abstr 371, 2013.
15. Burnight T, Wood CG, Tannir NM, Jonasch E, Pisters LL, Matin SF, Spelman A, Wei Q, Cohen. A randomized controlled trial of expressive writing for patients with renal cell carcinoma (RCC). J Clin Oncol 30(Suppl):abstr 9029, 2012.
16. Cauley DH, Atkinson BJ, Ng CS, Wang X, Xiao L, Corn PG, Jonasch E, Tannir NM. Everolimus (E) and temsirolimus (T) associated pneumonitis (P) in metastatic renal cell cancer patients (mRCC): A single-center experience. J Clin Oncol Suppl 5(abstr 401), 2012.
17. Malouf G, Monzon FA, Couturier J, Molinie V, Escudier BJ, Camparo P, Tamboli P, Wood CG, Tannir NM. Genomic analysis of translocation renal cell carcinoma: Association of frequent 3p loss and poor outcome. J Clin Oncol 30(Suppl 5):abstr 360, 2012.
18. Ho TH, Monzon FA, Hoang A, Tamboli P, Furge KA, Kydema K, Petillo D, Teh BT, Tannir NM, Hung MC, Jonasch E. Molecular characterization of SETD2, a histone methyltransferase, in clear cell renal cell carcinoma (ccRCC). J Clin Oncol 30(Suppl):abstr 4624, 2012.
19. Chapin BF, Delacroix SE, Kenney PA, Nogueras Gonzalez GM, Tamboli P, Jonasch E, Tannir NM, Wood CG. Nodal disease in the setting of metastatic renal cell carcinoma: Can a lymph node dissection alter outcomes?. J Clin Oncol 30(Suppl 5):abstr 386, 2012.
20. Matrana MR, Shetty AV, Atkinson BJ, Xiao L, Corn PG, Millikan RE, Jonasch E, Tannir NM. Outcomes of patients (pts) with metastatic renal cell carcinoma (mRCC) treated with pazopanib after progression on other targeted therapies (TT): A single-institution experience. J Clin Oncol 30(Suppl):abstr 4615, 2012.
21. Haddad H, Rini BI, Jonasch E, Tannir NM, Dreicer R, Garcia JA, Wood LS, Elson P. Post-axitinib systemic therapy in metastatic renal cell carcinoma (mRCC). J Clin Oncol 30(Suppl):abstr4609, 2012.
22. Ho TH, Monzon FA, Hoang A, Tamboli P, Furge KA, Dykema K, Petillo D, Teh BT, Tannir NM, Hung M-C, Jonasch E. Regulation of SETD2, a histone methyltransferase, in advanced clear cell renal cell carcinoma (ccRCC). J Clin Oncol 30(Suppl 5):abstr 368, 2012.
23. Matrana MR, Rao P, Atkinson BJ, Guo C, Tannir NM. Therapies and outcomes of non-renal cell carcinoma (non-RCC) neoplasms of the kidney: A single-institution experience. J Clin Oncol 30(Suppl 5):abstr 431, 2012.
24. Flaherty A, Matrana MR, Atkinson BJ, Tannir NM. Treatment of patients with metastatic renal cell carcinoma (RCC) and end-stage renal disease (ESRD) with targeted therapy (TT): A case series. J Clin Oncol 30(Suppl 5):abstr 453, 2012.
25. Rini BI, Szczylik C, Tannir NM, Koralewski P, Tomczak P, Deptala A, Kracht K, Sun Y, Puhlmann M, Escudier B. AMG 386 in combination with sorafenib in patients (pts) with metastatic renal cell cancer (mRCC): A randomized, double-blind, placebo-controlled, phase II study. J Clin Oncol 29(suppl 7):abstr 309, 2011.
26. Jonasch E, Alvarez K, Peterson L, Tannir NM, Sircar K, Tamboli P, Monzon FA. Chromosome 14q imbalances and pathways associated with resistance to antiangiogenic therapy in clear cell renal cell carcinoma. j Clin Oncol 29(suppl 7):abstr 339, 2011.
27. Cauley DH, Atkinson BJ, Corn PG, Jonasch E, Tannir NM. Everolimus-associated pneumonitis (EAP) in metastatic renal cell cancer patients (mRCC): A single-center experience. J Clin Oncol 29(suppl 7):abstr 332, 2011.
28. Richey SL, Culp SH, Jonasch E, Corn PG, Pagliaro LC, Matin SF, Wood CG, Tannir NM. Long-term survival of patients with metastatic renal cell carcinoma (mRCC) treated with targeted therapy (TT) without cytoreductive nephrectomy (CN). J Clin Oncol 29(suppl 7):abstr 346, 2011.
29. Matrana M, Atkinson B, Corn P, Jonasch E, Tannir MN. Metastatic RCC treated with pazopanib after progression on other targeted agents a single-institution experience. J Clin Oncol 29(suppl 7):abstr 351, 2011.
30. Tannir NM, Lim ZD, Rao P, Tamboli P, Atkinson B, Vaishampayan U, Plimack E, Rathmell K, Jonasch E. Outcome of patients with renal medullary carcinoma (RMC) treated in the era of targeted therapies (TT): A multicenter experience. J Clin Oncol 29(suppl 7):abstr 386, 2011.
31. Chapin BF, Wood CG, Jonasch E, Tannir N, Tamboli P, Culp SH, Delacroix SE, Gonzalez G. Timing of cytoreductive nephrectomy does not influence survival in metastatic renal cell carcinoma. Proceedings from AUA Annual Meeting, 2011.
32. Verma J, Jonasch E, Allen P. Tannir NM, Mahajan A. Tyrosine kinase inhibitors and development of brain metastasis in metastatic renal cell carcinoma: A retrospective review. J Clin Oncol 29(suppl 7):abstr 340, 2011.
33. Mahajan A, Verma JA, Jonasch E, Tannir N, Allen PK. Tyrosine kinase inhibitors and the treatment of brain metastases in metastatic renal cell carcinoma. Amer Radium Soc SS01(CNS Cancer):Abstract ID: 35411, 2011.
34. Abel E, Culp SH, Tannir NM, Matin SF, Tamboli P, Wood CG. Use of early primary tumor response to predict overall survival in patients with metastatic RCC undergoing treatment with sunitinib. J Clin Oncol 29(suppl 7):abstr 329, 2011.
35. Ilias-Khan NA, Khakoo AY, Tannir NM. A clinical and biological profile to predict risk of development of hypertension in patients with non-clear cell renal cell carcinoma treated with sunitinib. J Clin Oncol 28(15s):suppl; abstr 4601, 2010.
36. Wilhelm KL, Atkinson BJ, Khakoo AY, Tannir NM, Jonasch E. A retrospective evaluation of antiangiogenic therapy induced hypertension in metastatic renal cell carcinoma. J Clin Oncol 28:suppl; abstr e15047, 2010.
37. Monzon FA, Alvarez K , Amato RJ, Peterson L, Shen SS, Hernandez-McClain J, Sircar K, Tamboli P, Tannir NM, Jonasch E. Chromosomal imbalances as biomarkers for recurrence and antiangiogenic resistance in clear cell renal cell carcinoma. J Clin Oncol 28:suppl; abstr e15012, 2010.
38. Richey SL, Culp SH, Jonasch E, Corn PG, Pagliaro LC, Matin SF, Wood CG, Tannir NM. Outcome of patients (pts) with metastatic renal cell carcinoma (mRCC) treated with targeted therapy (TT) without cytoreductive nephrectomy (CN). J Clin Oncol 28(15s):suppl; abstr 4613, 2010.
39. Tannir NM, Wong Y, Kollmannsberger CK, Ernstoff MS, Perry DJ, Appleman LJ, E. M. Posadas, Qian J, Ricker JL, Michaelson D. Phase II trial of linifanib in patients with advanced renal cell cancer (RCC) after sunitinib failure. J Clin Oncol 28(15s):4527, 2010.
40. Jonasch E, Wood CG, Pagliaro LC, Corn PG, Aparicio A, Marcott VD, Matin SF, Tannir NM. Presurgical sunitinib in patients with newly diagnosed metastatic renal cell carcinoma (mRCC): Interim toxicity and feasibility analysis. J Clin Oncol 28:suppl; abstr e15083, 2010.
41. Plimack ER, Jonasch E, Bekele BN, Qiao W, Ng CS, Tannir NM. Sunitinib in papillary renal cell carcinoma (pRCC): Results from a single-arm phase II study. J Clin Oncol 28(15s):suppl; abstr 4604, 2010.
42. Dubauskas Lim Z, Choueiri TK, Hirsch MS, Jonasch E, Vaishampayan UN, Tamboli P, Corn PG, Heng DY, Tannir NM. Vascular endothelial growth factor (VEGF)-targeted therapy for the treatment of adult metastatic Xp11 translocation renal cell carcinoma. J Clin Oncol 28(15s):suppl; abstr 4606, 2010.
43. Heymach J, Jonasch E, Wang X, Du DZ, Yan S, Xu L, Herynk MH, McKee KS, Tran HT, Tannir NM, Zurita AJ. A cytokine and angiogenic factor (CAF) plasma signature for selection of sorafenib (SR) therapy in patients (pts) with metastatic renal cell carcinoma (mRCC). J Clin Oncol 27(15s):spllu; abstr 5114, 2009.
44. Montero AJ, Diaz-Montero CM, Liu J, Do K, Millikan RE, Tannir NM. Cytokines and angiogenic factors in metastatic renal cell cancer: Association of pre-treatment serum levels with survival. J Clin Oncol 27:suppl; abstr e16036, 2009.
45. Richey SL, Culp SH, Wood CG, Corn PG, Jonasch E, Tannir NM. Outcome of patients (pts) with metastatic renal cell carcinoma (mRCC) treated with systemic therapy without cytoreductive nephrectomy (CN). J Clin Oncol 27:suppl; abstr e16035, 2009.
46. Jonasch E, Tsavachidou D, Wood CG, Matin SF, Corn PG, Tamboli P, Wang X, Tannir N. Phase II presurgical study of bevacizumab plus erlotinib in untreated patients with metastatic renal cell carcinoma. J Clin Oncol 27(15s):suppl; abstr 5004, 2009.
47. Tannir N, Wong Y, Kollmannsberger C, Ernstoff MS, Perry DJ, Appleman LJ, Posadas E, Qian J, Ricker JL, Michaelson DM. Phase II trial of ABT-869 in advanced renal cell cancer (RCC) after sunitinib failure: Efficacy and safety results. J Clin Oncol 27(15s):suppl; abstr 5036, 2009.
48. Johnson ED, Tannir NM, Olejeme KA, Logothetis CJ, Jonasch E. Survival benefit in bevacizumab-based therapy in sickle cell trait patients diagnosed with renal medullary carcinoma. J Clin Oncol 27:suppl; abstr e16096, 2009.
49. Miller L, Lal LS, Tannir NM, DaCosta Byfield S, Atkinson B, Feng C, Lau JK, Yin L, Jonasch E. Treatment of poor-risk metastatic renal carcinoma patients with combination gemcitabine, capecitabine, and bevacizumab at a tertiary cancer center. J Clin Oncol 27:suppl; abstr e16112, 2009.
50. Plimack ER, Tannir N, Bekele BN, Lin E, Jonasch E. Patterns of progression in renal cell carcinoma: antivascular therapy compared with interferon. 2008 Genitourinary Cancers Symposium:393, 2008.
51. Araujo JC, Jonasch E, Tannir NM, Bekele BN, Lin E, Plimack ER. Patterns of progression in renal cell carcinoma: antivascular therapy compared with interferon. J Clin Oncol 26:5106, May 20 suppl, 2008.
52. Jonasch E, Wood CG, Matin S, Tamboli P, Do K. Pagliaro LC, Aparicio AM, Araujo JC, Tannir NM. Presurgical bevacizumab in patients with metastatic clear cell renal cell carcinoma: A phase II study. J Clin Oncol 26:5104, May 20 suppl, 2008.
53. Tsavachidou D, Tannir NM, Thomas C, Mills GB, Jonasch E. Reverse-phase protein array marker evaluation of protein expression patterns related to anti-angiogenesis treatment in renal cell carcinoma. J Clin Oncol 26:16016, May 20 suppl, 2008.
54. Plimack ER, Jonasch E, Bekele BN, Smith LA, Araujo JC, Tannir NM. Sunitinib in non-clear cell renal cell carcinoma (ncc-RCC): A phase II study. J Clin Oncol 26:5112, May 20 suppl, 2008.
55. Dutcher JP, Szczylik C, Tannir N, Benedetto P, Ruff P, Hsu A, Berkenblit A, Thiele A, Strahs A, Feingold J. Correlation of survival with tumor histology, age, and prognostic risk group for previously untreated patients for advanced renal cell carcinoma (adv RCC) receiving temsirolimus (TEMSR) or interferon-alpha (IFN). J Clin Oncol 25(18S):Abstract 5033, June 20 Supplement, 2007.
56. Matin S, Tannir N. Laparoscopic salvage nephrectomy after targeted neoadjuvant therapy for metastatic renal cell carcinoma: Initial results. J Clin Oncol 25(Moderated Poster Acceptance):Abstract 97323, 2007.
57. Jonasch E, Corn P, Ashe RG, Do D, Tannir NM. Randomized phase II study of sorafenib with or without low-dose IFN in patients with metastatic renal cell carcinoma. J Clin Oncol 25(18S):Abstract 5104, June 20 Supplement, 2007.
58. Montero AJ, Diaz-Montero C, Wang X, McIntyre BW, Tannir N. Predictive utility of serum cytokine levels in patients with metastatic renal cell carcinoma (MRCC) treated with interferon alfa (IFNa). J Clin Oncol 24:Abstract 14503, 2006.
59. Lina S, Wood CG, Zhang D, Tannir NM, Dinney CP, Wu X. Telomere dysfunction in peripheral lymphocytes as a predisposition factor for renal cancer. Proc Amer Assoc Cancer Res 26:4990, 2006.
60. Tannir NM, Jonasch E, McMichael C, Wang X, Wooten L, Ng CS. A phase II trial of gemcitabine plus capecitabine (GX) in patients with advanced renal cell cancer (mrcc) previously treated with immunotherapy. J Clin Oncol 23(16S):Abstract 4598, 2005.
61. Ebinghaus SW, Hussain M, Tannir NM, Gordon MS, Desai AA, Knight RA, Carlson DM, Giflin RA. A randomized phase 2 study of the thrombospondin-mimetic peptide ABT-510 in patients with previously untreated advanced renal cell carcinoma. J Clin Oncol 23(16S):Abstract 4607, 2005.
62. Jonasch E, Tu S-M, Tannir NM, Pagliaro LC, Mathew P, Siefker-Radtke AO, Wen S, General R, Lin S-H, Logothetis CJ. Bone-targeted therapy consisting of zoledronate, thalidomide, and gamma interferon in renal cell carcinoma: A phase II study. J Clin Oncol 23(16S):Abstract 4769, 2005.
63. Tannir NM, Cohen L, Wang X, Ng CS, Poulter VA, Mathew P, Siefker-Radtke AO, Jonasch E, Pagliaro LC, Millikan RE. A randomized phase III trial of low dose versus intermediate dose interferon alfa (IFN) as frontline therapy in advanced progressive renal cell cancer (RCC). J Clin Oncol 22(14S):Abstract 4607, 2004.
64. Siefker-Radtke AO, Thall PF, Tannir NM, Tu SM, Pagliaro, LC, Williams DL, Millikan, RE. Implementation of a novel statistical design to evaluate successive treatment courses for metastatic transitional cell carcinoma. A Phase II trial at the M D Anderson Cancer Center. J Clin Oncol 22(14S):Abstract 4543, 2004.
65. Ueno NT, Cheng YT, Giralt SA, RondÓn G, Gajewski JL, Tannir NM, Pagliaro LC, Hortobagyi GN, Champlin RE. Complete donor chimerism by fludarabine/melphalan in mini-allogeneic transplantation for metastatic renal cell carcinoma (RCC) and breast cancer (BC). J Clin Oncol 20:Abstract #1659, 2002.

Book Chapters

1. Kovitz C, Spiess PE, Tannir NM. Germ Cell Tumors. In: Encyclopedia of Cancer: Germany. In Press.
2. Masterson J, Fisch M and Tannir N. Palliative interventions. In: Renal Cancer. Ed(s) Eisen T. Oxford University Press: Cambridge, UK. In Press.
3. Matrana M, Atkinson B, Tannir NM. Combinatorial and sequential targeted therapy in metastatic renal cell carcinoma. In: Kidney Cancer, Principles and Practices. Ed(s) PN Lara Jr, E. Jonasch. Springer-Verlag Berlin: Berlin Heidelberg Germany, 225-239, 2012. ISBN: 978-3-642-21857-6.
4. Jonasch E, Matin SF, Pagliaro LC, Wood CG, Tannir NM. Renal Cell Carcinoma. In: The MD Anderson Manual of Medical Oncology, Second. Ed(s) HM Kantarjian, RA Wolff, CA Koller. McGraw Hill Medical, 905-23, 2011. ISBN: 978-0-07-170106-8.
5. Chowdhury S, Matrana MR, Tsang C, Atkinson B, Choueiri TK, Tannir MN. Systemic therapy for metastatic non-clear-cell renal cell carcinoma: Recent progress and future directions. In: Hematology/Oncology Clinics of North America: Renal Cell Cancer. 25, 4. Ed(s) GP Canellos, N Berliner; Guest Editor: TK Choueiri. W. B. Saunders Company, 853-869, 2011. ISBN: 13: 978-1-4557-1103-1.
6. Dayyani F, Tannir NM. Targeted Genitourinary Cancers. In: Targeted Therapy for Solid Tumors and Hematologic Malignancies, Cancer Etiology, Diagnosis and Treatments. Ed(s) A.Q. Cardama, D.L. Gibbons, V. Cataldo. Nova Science Publishers, Inc., 187-211, 2011. ISBN: 978-1-6171-854-3.
7. Tannir N, O'Brien S, Keating M. Diagnosis and treatment of chronic lymphocytic leukemia. In: Neoplastic Diseases of the Blood, Fourth, 83-95, 2003.

Books (edited and written)

1. Wu X, Shu X, Chow W-H, Gu J, Rao P, Tamboli P, Ho TH, Dere R, Walker CL, Kalra S, Jonasch E, Sabir SH, Tam AL, Matin SF, Kim DY, Karam JA, Wood CG, Gayed BA, Margulis V, Gunturi A, McDermott DF, Eisen T, Skoulidis F, Pal SK, Choueiri TK, Chism DD, Rathmell WK, Atkinson B, Cauley D, Ghia AJ, Choi S, Yennurajalingam S, Chaoul A, Lopez G, Lee R, Garcia MK, Cohen L, Philips GK, Atkins MB. Ed(s) Nizar M. Tannir. Renal Cell Carcinoma. In: Oxford American Oncology Library. 1, First. Oxford University Press: United States of America, 2014.

Letters to the Editor

1. Tannir NM, Thall P, Millikan RE. Reply from Authors re: Camillo Porta. How to Identify Active Novel Agents in Rare Cancers and then Make Them Available: A Need for a Paradigm Shift. Eur Urol 2012;62:1020-1: Research in Rare Tumors: A Need for a Paradigm Shift. Eur Urol 62(6):1022, 12/2012. e-Pub 8/2012. PMID: 22925576.
2. Richey SL, Culp SH, Jonasch E, Matin SF, Wood CG, Tannir NM. Reply to Benefit of cytoreductive nephrectomy in metastatic RCC: do we learn from retrospective studies and small prospective studies? Ann Oncol 22(5):1243, 5/2011. PMID: 21521725.

Grant & Contract Support

Title: Molecular genetic and epigenetic characterization of translocation renal-cell carcinoma (RCC): Comparison of pediatric and adult forms
Funding Source: Kidney Cancer Research Group
Role: Principal Investigator
Duration: 2/1/2012 - 1/30/2013
 
Title: Molecular genetic and epigenetic characterization of translocation renal-cell carcinoma (RCC): Comparison of pediatric and adult forms
Funding Source: Kidney Cancer Research Group
Role: Principal Investigator
Duration: 10/1/2010 - 9/30/2011

Last updated: 3/16/2015